DPYD antibody (AA 265-370) (Alexa Fluor 594)

Catalog No. ABIN2812517

Product Details anti-DPYD Antibody (Alexa Fluor 594)

Target: DPYD (Dihydropyrimidine Dehydrogenase (DPYD))

Binding Specificity: AA 265-370

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This DPYD antibody is conjugated to Alexa Fluor 594

Application: Western Blotting (WB), Immunofluorescence (Paraffin-embedded Sections) (IF (p)), Immunofluorescence (Cultured Cells) (IF (cc))

Predicted Reactivity: Human,Mouse,Rat,Dog,Cow,Sheep,Pig,Horse,Rabbit

Purification: Purified by Protein A.

Immunogen: KLH conjugated synthetic peptide derived from human DPYD

Isotype: IgG

Application Details

Application Notes: IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 μg/μL

Buffer: Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.

Preservative: ProClin

Precaution of Use: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Storage: -20 °C

Storage Comment: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Expiry Date: 12 months

Target Details for DPYD

Target: DPYD (Dihydropyrimidine Dehydrogenase (DPYD))

Alternative Name: DPYD (DPYD Products)

Synonyms: DPYD antibody, dpyd antibody, zgc:77205 antibody, AI315208 antibody, DPD antibody, E330028L06Rik antibody, DHP antibody, DHPDHASE antibody, dhp antibody, dhpdhase antibody, dpd antibody, 14.t00017 antibody, DDBDRAFT_0189681 antibody, DDBDRAFT_0231100 antibody, DDB_0189681 antibody, DDB_0231100 antibody, dpyda antibody, zgc:153505 antibody, dihydropyrimidine dehydrogenase antibody, dihydropyrimidine dehydrogenase b antibody, dihydropyrimidine dehydrogenase L homeolog antibody, dihydropyrimidine dehydrogenase [NADP(+)] antibody, dihydropyrimidine dehydrogenase a, tandem duplicate 1 antibody, DPYD antibody, Dpyd antibody, dpydb antibody, dpyd.L antibody, EHI_012980 antibody, LOC5573038 antibody, EDI_044620 antibody, pyd1 antibody, dpyda.1 antibody

Background:

Synonyms: DHP, DHPDHase, Dihydropyrimidine dehydrogenase [NADP+], Dihydropyrimidine dehydrogenase, Dihydrothymine dehydrogenase, Dihydrouracil dehydrogenase, DPD, DPYD, DPYD_HUMAN, MGC132008, MGC70799, OTTHUMP00000058954.

Background: Dihydropyrimidine dehydrogenase (DPYD) catalyzes the first rate-limiting step of the NADPH-dependent catabolism of uracil and thymine to dihydrouracil and dihydrothymine, thus, a deficiency of DPYD leads to an accumulation of uracil and thymine. Abnormal concentrations of these metabolites in bodily fluids may be the cause of neurological disease and a contraindication for treatment of cancer patients with certain pyrimidine analogs. DPYD also catalyzes the anticancer agent 5-fluorouracil (5-FU) pathway and is involved in the efficacy and toxicity of 5-FU. Variations in DPYD concentration may arise from alterations at the transcriptional level of the dihydropyrimidine dehydrogenase gene. Specifically, hypermethylation of the DPYD promoter downregulates dihydropyrimidine dehydrogenase expression. Deficient DPYD alleles may constitute a risk factor for severe toxicity following treatment with 5-FU.Involvement in disease:Defects in DPYD are the cause of dihydropyrimidine dehydrogenase deficiency (DPYD deficiency) , also known as hereditary thymine-uraciluria or familial pyrimidinemia. DPYD deficiency is a disease characterized by persistent urinary excretion of excessive amounts of uracil, thymine and 5-hydroxymethyluracil. Patients suffering from this disease show a severe reaction to the anticancer drug 5-fluorouracil. This reaction includes stomatitis, Leukopenia, thrombocytopenia, hair loss, diarrhea, fever, marked weight loss, cerebellar ataxia, and neurologic symptoms, progressing to semicoma.

Gene ID: 1806

Pathways: Ribonucleoside Biosynthetic Process